📰 7 sources covering this story

AstraZeneca Ends Phase 3 Lung Cancer Drug Trial After Review - WSJ

First covered 6 hrs ago · latest take 3 hrs ago. Compare how each outlet is covering it — and rate the sources you trust.

AstraZeneca Ends Phase 3 Lung Cancer Drug Trial After Review - WSJ
AstraZeneca Ends Phase 3 Lung Cancer Drug Trial After Review - WSJ
AstraZeneca Ends Phase 3 Lung Cancer Drug Trial After Review  WSJ
The Times
The Times4 hrs ago
AstraZeneca posts two wins and a setback for lung cancer pipeline
AstraZeneca posts two wins and a setback for lung cancer pipeline  The Times
Irish News
Irish News5 hrs ago
AstraZeneca ditches lung cancer treatment trial
The FTSE 100 firm stopped a stage volrustomig drug trial a month after halting a trial for a new heart disease treatment.
AstraZeneca ditches lung cancer treatment trial
The FTSE 100 firm stopped a stage volrustomig drug trial a month after halting a trial for a new heart disease treatment.
AstraZeneca ditches lung cancer treatment trial
The FTSE 100 firm stopped a stage volrustomig drug trial a month after halting a trial for a new heart disease treatment.
Reuters
Reuters🏁 first to report6 hrs ago
AstraZeneca to discontinue late-stage lung cancer trial for volrustomig
AstraZeneca to discontinue late-stage lung cancer trial for volrustomig  Reuters
Top rated outlets
Outlets are ranked once they have 3+ community ratings — be one of the first to rate.
🏆 Most trusted sources 2026 →
Scores come entirely from reader ratings — rate the sources you read to shape them. How it works →